Director David H. Deming filed a Form 4 with the SEC on November 12, 2026, disclosing open-market purchases of Phio Pharmaceuticals Corp. common stock on November 10 and November 11, 2026.

Key Highlights

  • First purchase: David H. Deming acquired 6,800 shares on November 10, 2026, at a weighted average price of $0.8395 per share, with individual transaction prices ranging from $0.8079 to $0.8600.
  • Second purchase: Deming acquired an additional 5,200 shares on November 11, 2026, at a weighted average price of $0.838 per share, with individual transaction prices ranging from $0.8269 to $0.8600.
  • Total shares acquired: 12,000 shares across the two trading days, both coded as open-market purchases (transaction code P).
  • Resulting ownership: Following both transactions, Deming reported beneficial ownership of 49,800 shares of common stock, held directly, including shares underlying unvested restricted stock units.
  • Relationship to issuer: Deming is identified in the filing solely as a Director of Phio Pharmaceuticals Corp. (NASDAQ:PHIO).

Deming's Two-Day Open-Market Purchases in Phio Pharmaceuticals

According to the filing, David H. Deming, a director of Phio Pharmaceuticals Corp. (NASDAQ:PHIO), purchased shares of the company's Common Stock, $0.0001 par value, across two consecutive trading sessions. On November 10, 2026, the filing discloses 6,800 shares were acquired at a weighted average price of $0.8395, with individual prices ranging from $0.8079 to $0.8600 per share. The filing notes the transactions were executed in multiple separate purchases within that range.

On November 11, 2026, the filing reports an additional 5,200 shares were purchased at a weighted average price of $0.838 per share, with individual prices ranging from $0.8269 to $0.8600. Both sets of transactions carry transaction code "P," indicating open-market purchases. The filing was signed by Lisa C. Carson as attorney-in-fact on November 12, 2026.

After both transactions, the filing states Deming directly held 49,800 shares of beneficial ownership. The filing includes a footnote clarifying that this total "includes shares of common stock underlying unvested restricted stock units." The filing also notes that Deming undertakes to provide full information on the number of shares purchased at each separate price upon request by the issuer, any security holder, or SEC staff.

What Was Disclosed

Phio Pharmaceuticals Corp. director David H. Deming disclosed two open-market purchases totaling 12,000 shares of common stock on November 10 and November 11, 2026, resulting in reported beneficial ownership of 49,800 shares, including shares underlying unvested restricted stock units.